Dr. Mardin (Asghar) Fallah
Founder and CEO
More about
Mardin is an accomplished scientist and visionary entrepreneur with deep expertise in RNA technology and regenerative medicine. As the founder and CEO of RNARevive Therapeutics, he leads the company’s mission to transform bone health through innovative RNA-based therapies. With a strong background in biotechnology and a dedication to addressing chronic bone conditions like osteoporosis, Mardin combines scientific rigor with strategic insight to advance groundbreaking treatments. His commitment to bridging laboratory discoveries with real-world impact drives RNARevive’s efforts to bring life-changing therapies to patients globally.
Dr. Peter Kannu
Chief Clinical Scientist
More about
Dr. Peter Kannu is a leading expert in clinical science with a focus on bone health and regenerative medicine. As the Chief Clinical Scientist at RNARevive Therapeutics, Peter oversees the clinical development of RNA-based therapies, guiding research from the lab to impactful treatments for patients. With a wealth of experience in translational medicine and clinical research, he is dedicated to advancing innovative therapies that address chronic bone conditions and improve patient outcomes globally.
Nina Karpoff
Head of Business Development and Strategy
More about
Nina Karpoff brings extensive experience in business development, strategic planning, and biotech partnerships to RNARevive Therapeutics. As the Head of Business Development and Strategy, she drives the company’s growth initiatives, fostering collaborations and guiding strategic direction to expand RNARevive’s impact in the biotechnology field. With a keen understanding of market dynamics and a passion for innovation, Nina plays a pivotal role in positioning RNARevive as a leader in RNA-based therapeutics for bone health.
Ehsan Misaghi
Head of Engineering and AI Development
More about
Ehsan Misaghi is an MD/PhD student at the University of Alberta with a multifaceted background spanning genetics, medicine, artificial intelligence, ophthalmology, neuroscience, and biomedical/electrical engineering. His research focuses on the genetic correlates of ocular diseases, exploring the intricate role of genetic factors in eye health and pioneering the development of RNA-based therapeutics for ocular disorders. Ehsan has published multiple manuscripts in peer-reviewed journals, and his work has been recognized with numerous awards at national and international levels. Ehsan is also the co-founder and Director of Programs and Initiatives at the Artificial Intelligence in Medical Systems Society, where he leverages his expertise to explore the transformative potential of AI in medicine. At RNARevive Therapeutics, Ehsan is spearheading the integration of AI into RNA-based therapeutic development, advancing innovation in the field of regenerative medicine. His current focus includes using AI to design and optimize RNA therapeutics for treating ocular diseases.